JennifersHope
New member
<a target=_blank class=ftalternatingbarlinklarge href="http://www.cf-dk.org/CFwwwNEWS/cfwwwnews.htm
">http://www.cf-dk.org/CFwwwNEWS/cfwwwnews.htm
</a>
Click on the link if you are interested.. It really is frustrating...Here is an part of it
" Despite these developments, however, Chiron has not come out with a new drug-device combination using a new nebulizer and has instead continued to promote TOBI, which enjoys a dominant market position, according to court documents. Under FDA regulations, TOBI can only be sold with older nebulizer versions."
Chiron's medical-method patent aimed to prevent the new generation of nebulizers from being used with tobramycin, or at least from using those treatment methods within the limits of the claims.
In May 2005, Chiron brought charges against a group of compounding pharmacies and distributors - SourceCF Inc., Maxor National Pharmacy Services Corporation (IV Solutions), Foundation Care LLC, and Pharmaceutical Specialities Inc- alleging the companies infringed on the `907 patent by selling a product called the eFlow inhaler and instructing doctors and cystic fibrosis victims on how to use it.
">http://www.cf-dk.org/CFwwwNEWS/cfwwwnews.htm
</a>
Click on the link if you are interested.. It really is frustrating...Here is an part of it
" Despite these developments, however, Chiron has not come out with a new drug-device combination using a new nebulizer and has instead continued to promote TOBI, which enjoys a dominant market position, according to court documents. Under FDA regulations, TOBI can only be sold with older nebulizer versions."
Chiron's medical-method patent aimed to prevent the new generation of nebulizers from being used with tobramycin, or at least from using those treatment methods within the limits of the claims.
In May 2005, Chiron brought charges against a group of compounding pharmacies and distributors - SourceCF Inc., Maxor National Pharmacy Services Corporation (IV Solutions), Foundation Care LLC, and Pharmaceutical Specialities Inc- alleging the companies infringed on the `907 patent by selling a product called the eFlow inhaler and instructing doctors and cystic fibrosis victims on how to use it.